Genetic association studies of ACE and PAI-1 genes in women with recurrent pregnancy loss

Summary

A fine balance between coagulation and fibrinolysis is critical in early pregnancy. Plasminogen activator inhibitor-1 (PAI-1) and angiotensin converting enzyme (ACE) are involved in the fibrinolytic process, and several studies have reported the association between their gene polymorphisms and recurrent pregnancy loss (RPL). This study was conducted to investigate the association between PAI-1 and ACE polymorphisms and idiopathic RPL, using meta-analyses. A systematic review of the published literature from the MEDLINE and EMBASE databases before April 2012 was conducted. Of 209 potentially relevant studies, 22 case-control studies comprising a total of 2,820 RPL patients and 3,009 controls were included. Among these studies were 11 reports of PAI-1 4G/5G and 11 of ACE I/D polymorphisms in patients with RPL. A significant association was found withthe ACE I/D polymorphism [summary odds ratio 1.29 (95% confidence interval 1.02–1.62)] in studies including more than two recurrent abortions. Subgroup analysis did not show significant associations with RPL in Caucasian and non-Caucasian patients. Meta-analyses of PAI-1 4G/5G polymorphism were not found associations with RPL in studies including more than two or three recurrent abortions, and in studies of Caucasian and non-Caucasian patients. In conclusion, meta-analyses showed a significant association between the ACE I/D polymorphism and idiopathic RPL. High clinical heterogeneity existed among studies of PAI-1 4G/5G, and the aggregated data failed to confer higher susceptibility to idiopathic RPL. More well-designed studies with different ethnic populations are required for future integration.

Keywords

Meta-analysis - fibrinolysis - coagulation - ACE - PAI-1 - recurrent pregnancy loss

• References

• 1 Baek KH. et al. Recurrent pregnancy loss: the key potential mechanisms. Trends Mol Med 2007; 13: 310-317. DOI:10.1016/j.molmed.2007.05.005.
• 2 Goodman CS. et al. Which thrombophilic gene mutations are risk factors for recurrent pregnancy loss?. Am J Reprod Immunol 2006; 56: 230-236. DOI:10.1111/j.1600-0897.2006.00419.x.
• 3 Coulam CB. et al. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006; 55: 360-368. DOI:10.1111/j.1600-0897.2006.00376.x.
• 4 Lussana F. et al. Pregnancy-related venous thromboembolism: Risk and the effect of thromboprophylaxis. Thromb Res 2012; 129: 673-680. DOI:10.1016/j.thromres.2012.01.017.
• 5 Kutteh WH, Triplett DA. Thrombophilias and recurrent pregnancy loss. Semin Reprod Med 2006; 24: 54-66. DOI:10.1055/s-2006-931801.
• 6 Conserva V. et al. Recurrence and severity of abnormal pregnancy outcome in patients treated by low-molecular-weight heparin: a prospective pilot study. J Matern Fetal Neonatal Med. 2012; in press
• 7 Preston FE. et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-916. DOI:10.1016/S0140-6736(96)04125-6.
• 8 Buchholz T, Thaler CJ. Inherited thrombophilia: impact on human reproduction. Am J Reprod Immunol 2003; 49: 1-13. DOI:10.1034/j.1600-0897.2003.01149.x.
• 9 Reynolds LP, Redmer DA. Angiogenesis in the placenta. Biol Reprod 2001; 64: 1033-1040. DOI:10.1095/biolreprod64.4.1033.
• 10 Schiessl B. et al. Localisation of angiogenic growth factors and their receptors in the human placental bed throughout normal human pregnancy. Placenta 2009; 30: 79-87. DOI:10.1016/j.placenta.2008.10.004.
• 11 Floridon C. et al. Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies. Placenta 2000; 21: 754-762. DOI:10.1053/plac.2000.0573.
• 12 Sartori MT. et al. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998; 80: 956-960.
• 13 Festa A. et al. Promoter (4G / 5G) plasminogen activator inhibitor-1 genotype and plasminogen activator-1 levels in blacks, Hispanics and non Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 2003; 20: 2422-2427. DOI:10.1161/01.CIR.0000066908.82782.3A.
• 14 Ridker PM. et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II Evidence of a potential interaction between the rennin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-1973. DOI:10.1161/01.CIR.87.6.1969.
• 15 Kim DK. et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 1997; 17: 3242-3247. DOI:10.1161/01.ATV.17.11.3242.
• 16 Rigat B. et al. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounts for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346. DOI:10.1172/JCI114844.
• 17 Ueda S. et al. Enhanced pressor response to angiotensin I in normotensive men with the ACE deletion allele. Hypertension 1995; 25: 1266-1269. DOI:10.1161/01.HYP.25.6.1266.
• 18 Fatini C. et al. Angiotensin converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. Blood Coagul Fibrinolysis 2000; 11: 657-662. DOI:10.1097/00001721-20001000584-00010.
• 19 Mello G. et al. Maternal-fetal flow, negative events, and preeclampsia: role of ACE I/D polymorphism. Hypertension 2003; 41: 932-937. DOI:10.1161/01.HYP.0000063146.40351.AD.
• 20 Dossenbach-Glaninger A. et al. ACE I/D polymorphism and recurrent first trimester pregnancy loss: interaction with SERPINE1 4G/5G and F13 Val34Leu polymorphisms. Br J Haematol 2008; 141: 269-271. DOI:10.1111/j.1365-2141.2008.07058.x.
• 21 Goodman C. et al. Are polymorphisms in the ACE and PAI-1 genes associated with recurrent spontaneous miscarriages?. Am J Reprod Immunol 2009; 62: 365-370. DOI:10.1111/j.1600-0897.2009.00744.x.
• 22 Al Sallout RJ, Sharif FA. Polymorphisms in NOS3, ACE and PAI-1 genes and risk of spontaneous recurrent miscarriage in the Gaza Strip. Med Princ Pract 2010; 19: 99-104. DOI:10.1159/000273067.
• 23 Aarabi M. et al. Polymorphisms of plasminogen activator inhibitor-1, angiotensin converting enzyme and coagulation factor XIII genes in patients with recurrent spontaneous abortion. J Matern Fetal Neonatal Med 2011; 24: 545-548. DOI:10.3109/14767058.2010.511331.
• 24 Prisco D. et al. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. Int J Clin Lab Res 2000; 30: 179-185. DOI:10.1007/s005990070004.
• 25 Ince DA. et al. The role of plasminogen activator inhibitor-1 and angiotensin-converting enzyme gene polymorphisms in bronchopulmonary dysplasia. Genet Test Mol Biomarkers 2010; 14: 643-647. DOI:10.1089/gtmb.2010.0072.
• 26 Güngör Y. et al. The presence of PAI-1 4G/5G and ACE DD genotypes increases the risk of early-stage AVF thrombosis in hemodialysis patients. Ren Fail 2011; 33: 169-175. DOI:10.3109/0886022X.2011.552151.
• 27 Agirbasli M. et al. Multifactor dimensionality reduction analysis of MTHFR, PAI-1, ACE, PON1, and eNOS gene polymorphisms in patients with early onset coronary artery disease. Eur J Cardiovasc Prev Rehabil 2011; 18: 803-809.
• 28 Bora E. et al. Plasminogen activator inhibitor-1 and angiotensin converting enzyme gene polymorphisms in Turkish asthmatic children. Allergol Immunopathol. 2012; in press
• 29 Sotiriadis A. et al. Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol 2007; 109: 1146-1155. DOI:10.1097/01.AOG.0000260873.94196.d6.
• 30 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 07: 177-188. DOI:10.1016/0197-2456(86)90046-2.
• 31 Higgins JP. et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560. DOI:10.1136/bmj.327.7414.557.
• 32 Egger M. et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634. DOI:10.1136/bmj.315.7109.629.
• 33 Zhang S. et al. Strong association between angiotensin I-converting enzyme I/D polymorphism and unexplained recurrent miscarriage of Chinese women—a case-control study. Reprod Sci 2011; 18: 743-746. DOI:10.1177/1933719111415865.
• 34 Ivanov P. et al. Plasminogen activator inhibitor type 1 activity in women with unexplained very early recurrent pregnancy loss. Akush Ginekol 2010; 49: 3-8.
• 35 Ivanov P. et al. Combined thrombophilic factors among women with late recurrent spontaneous abortions. Akush Ginekol 2011; 50: 8-12.
• 36 Alhenc-Gelas F. et al. The renin-angiotensin system in pregnancy and parturition. Adv Nephrol Necker Hosp 1986; 15: 25-33.
• 37 Vaughan DE. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease. Eur Heart J 1998; 19: 9-12.
• 38 Suzuki Y. et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881-900. DOI:10.1016/S1357-2725(02)00271-6.
• 39 Vaughan DE. et al. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin±angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001. DOI:10.1172/JCI117809.
• 40 Fatini C. et al. ACE DD genotype: an independent predisposition factor to venous thromboembolism. Eur J Clin Invest 2003; 33: 642-647. DOI:10.1046/j.1365-2362.2003.01185.x.